Patent ID: 11944643
Assignee: CELLECTIS SA
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. An engineered human Universal Chimeric Antigen Receptor T Cell specific for CD22 (UCART22) comprising a Chimeric Antigen Receptor specific for CD22 (anti-CD22 CAR), and a safety switch;
wherein said anti-CD22 CAR comprises:
(i) at least one extracellular domain comprising a hinge domain from CD8alpha, and an antigen binding domain specific for CD22;
(ii) a transmembrane domain from CD8alpha; and
(iii) an intracellular signaling domain;

wherein said anti-CD22 CAR comprises a polypeptide sequence having at least 80% sequence identity with a full-length sequence of SEQ ID NO: 15; and
wherein said safety switch comprises:
(i) an RQR8 region linked to the anti-CD22 CAR by a cleavable peptide 2A linker, wherein the RQR8 region comprises the sequence of SEQ ID NO: 60;
(ii) at least two rituximab mAb-specific epitopes located between the antigen binding domain and the hinge domain of the anti-CD22 CAR;
(iii) three rituximab mAb-specific epitopes linked to the anti-CD22 CAR; or
(iv) three rituximab mAb-specific epitopes and one QBEND-10 mAb-specific epitope linked to the anti-CD22 CAR.